Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Strengthens Diabetes Pipeline With Two Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

A late-stage deal for a type 1 treatment and an early-stage deal for a series of type 2 compounds help J&J's move into diabetes, where it has traditionally been strong in blood glucose monitoring.
Advertisement

Related Content

A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
J&J Sees Growth Opportunities Through Partnerships And Emerging Markets After Facing Early Patent Cliff
Big Pharma Tries Out New Class On The Diabetes Block: SGLT-2
Big Pharma Tries Out New Class On The Diabetes Block: SGLT-2
J&J Deal With Metabolex Brings Late-Stage Diabetes Candidate To Pipeline

Topics

Advertisement
UsernamePublicRestriction

Register

PS070794

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel